^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD28 agonist

    Related drugs:
    1d
    COMBINE-EGFR-1: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (clinicaltrials.gov)
    P1/2, N=933, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Dec 2026 --> Apr 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc) • Lonsurf (trifluridine/tipiracil)
    28d
    MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. (PubMed, Future Oncol)
    Here, we present the protocol design for study MDX-2001-101, a multicenter, open-label, phase I/IIa clinical trial designed to evaluate the safety, tolerability, and antitumor effects of MDX2001 in patients with advanced solid tumors. The study comprises a phase Ia dose escalation guided by a Bayesian optimal interval design with a targeted maximum tolerated dose toxicity rate of 30%, a phase Ib dose expansion, and a phase IIa indication expansion.
    P1/2 data • Journal • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    1m
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=235 --> 70 | Trial completion date: Nov 2027 --> Aug 2026 | Trial primary completion date: Nov 2027 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    2ms
    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    2ms
    Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=400, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    alveltamig (ZG006)
    2ms
    This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, ModeX Therapeutics, An OPKO Health Company
    New P1/2 trial
    3ms
    A novel B7-H4/CD3/CD28 trispecific antibody with the SpyTag-SpyCatcher technology suppresses the growth of colorectal cancer. (PubMed, Int Immunopharmacol)
    Furthermore, SpyCatcher-SpyTag technology was introduced to combine the intact B7-H4 antibody with the anti-CD3/CD28 antibody, which are elements of the CD38 × CD28 × CD3 (SAR442257) TsAb, to create a new TsAb named TsAb-B7-H4...Moreover, TsAb-B7-H4 did not induce the infammatory cytokines which produced by human PBMCs. Consequently, we successfully engineered TsAb-B7-H4 which showed antitumor efficacy in CRC.
    Journal • IO biomarker
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    SAR442257
    3ms
    RNDO-564-001: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (clinicaltrials.gov)
    P1, N=149, Recruiting, Rondo Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab)
    4ms
    RNDO-564-001: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (clinicaltrials.gov)
    P1, N=149, Not yet recruiting, Rondo Therapeutics
    New P1 trial
    |
    Keytruda (pembrolizumab)
    4ms
    R5678-ONC-1879: A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (clinicaltrials.gov)
    P1/2, N=345, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jul 2026 --> Nov 2027 | Trial primary completion date: Aug 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Libtayo (cemiplimab-rwlc) • nezastomig (REGN5678)
    4ms
    A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=250, Recruiting, Janssen Research & Development, LLC | N=130 --> 250
    Enrollment change
    |
    pasritamig (JNJ-8343)
    4ms
    A Study of CC312 for Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=6, Recruiting, CytoCares Inc
    New P1 trial